JW Pharmaceutical said it acquired 2 million shares, representing 100% of Solidus Investment, for 30.728 billion won, or 8% of its equity capital. Solidus is a venture capital firm investing in biotechnology companies, and JW Pharmaceutical said the acquisition will help secure new growth momentum. The transaction follows JW Holdings’ 30.6 billion-won acquisition of the investment firm earlier this year, reportedly from CHA Bio Group, before transferring the stake to JW Pharmaceutical. The latest deal shifts the group’s corporate venture capital operations into its main operating company and is intended to strengthen biotech investment and open innovation. The source refers to the firm as Solidus Investment but later uses the name Solist Investment.